On 2 November 2011 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.
Recommended Reading
-
The European Medicines Agency (EMA) has issued a positive opinion for a new Wegovy® 7.2 mg dose, advancing its availability in the European Union (EU)
Read More -
Novo Nordisk and Akero Therapeutics Inc. today announced that Novo Nordisk’s acquisition of Akero, announced on 9 October 2025, has been completed
Read More